Date: Monday, July 21st, 2014
Venue: Clinical University Hospital of Santiago de Compostela (room 1, floor 0)
, New York, USA
is currently Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes and has published seminal papers in NEJM, JAMA, Lancet Oncology, J Clin Oncol or Chest among many others, and is a member of renowned scientific boards at the USA. He is also attending physician at the MSKCC.
research group, Health Research Institute of Santiago de Compostela (IDIS)
Summary: Lung cancer screening is currently a hot topic for many medical specialties (neumologists, oncologists, epidemiologists, radiologists and thoracic surgeons, among others). The, published in the NEJM in 2011 was the first randomized clinical trial in demonstrating that reduced lung cancer and overall mortality in smokers and former smokers when compared with Chest X-Rays. Following these results many scientific societies, especially in the USA, have recommended lung cancer screening for smokers and former smokers, between 55-74. Nevertheless, the balance between benefits and harms is unclear, with overdiagnosis, radiation induced cancers and lack of significant downstaging with screening being the main shortcomings.